A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Eeva RahkoArja Jukkola

Abstract

This study evaluates the prognostic and predictive relevance of a mutated p53 in a series of 254 samples from primary breast cancer patients. C-erbB-2 analysis was defined in a limited subpopulation of 79 patients. p53 and c-erbB-2 status was analysed by immunohistochemical staining of the tumour samples. Positive p53 immunostaining was present in 86 cases (34%) and correlated with a high malignant grade, negative progesterone receptor status and ductal histology of tumour. C-erbB-2 positivity was seen in 38 samples (48%). Within an average follow-up time of 74 months, 121 patients developed recurrent or metastatic disease. Patients with mutated p53 showed a statistically significant shorter overall survival and disease-free survival in both univariate and multivariate analyses. The worst clinical outcome was seen in patients who were both p53- and c-erbB-2-positive. The response rate to anthracycline-based chemotherapy in metastatic disease was low in the p53-positive cases. Our results help to clarify the independent prognostic role of a mutated p53 status in breast cancer patients, indicating that this gene might be predictive of anthracycline resistance. Patients with a mutant p53 status and overexpressing c-erbB-2 should b...Continue Reading

Citations

Sep 30, 2005·Cancer Chemotherapy and Pharmacology·Silwan ChedidMassimo Cristofanilli
Apr 30, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Tieshan JiangMarco Mascini
Jan 28, 2004·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Milena Gasco, Tim Crook
Jul 24, 2012·Carcinogenesis·Dawid WalerychGiannino Del Sal
Jul 18, 2009·Genes & Development·Hai JiangMichael T Hemann
Jun 23, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan F LaraUNKNOWN Cancer and Leukemia Group B
Jan 22, 2011·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Canfeza SezginRuchan Uslu
Sep 16, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ayman KhdairJayanth Panyam
Jun 7, 2008·Expert Review of Anticancer Therapy·Radha Todd, John Lunec
Jan 26, 2011·The Journal of Cell Biology·Patricia A J MullerJim C Norman
May 26, 2018·Cell Death & Disease·Alisha YallowitzNatalia Marchenko
Feb 24, 2020·Cell Communication and Signaling : CCS·Adam S Dayoub, Rolf A Brekken
Jan 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Narasimhan P AgaramCristina R Antonescu
Jan 13, 2015·Molecular Cancer Research : MCR·Alisha R YallowitzNatalia Marchenko
Feb 18, 2020·Trends in Cancer·Ashkan ShahbandiJames G Jackson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.